Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oncoinvent ASA's revenue for the
six
months ended in Dec. 2025 was kr11.35 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was kr16.07 Mil.
Oncoinvent ASA's Revenue per Share for the
six
months ended in Dec. 2025 was kr7.51.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr15.25.
Warning Sign:
Oncoinvent ASA revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Oncoinvent ASA was 70.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -12.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -28.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 11 years, Oncoinvent ASA's highest 3-Year average Revenue per Share Growth Rate was -12.50% per year. The lowest was -68.50% per year. And the median was -40.80% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Oncoinvent ASA Revenue Related Terms
Oncoinvent ASA Revenue Historical Data
* Premium members only.
The historical data trend for Oncoinvent ASA's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ONCINO vs VRTX, REGN, RVMD: Revenue Comparison
For the Biotechnology subindustry, Oncoinvent ASA's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Revenue distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr16.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (CHIX:ONCINO) has a Revenue of kr16.07 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncoinvent ASA and its competitors.
Is Oncoinvent ASA's Revenue too high?
Oncoinvent ASA's current Revenue is kr16.07 Mil. Overall, Oncoinvent ASA has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's Revenue compare to VRTX and REGN?
Oncoinvent ASA's Revenue of kr16.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Oncoinvent ASA and its competitors. Oncoinvent ASA's current Revenue is kr16.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (CHIX:ONCINO) has a current Revenue of kr16.07 Mil. The stock's GF Value™ is kr11,961.53, compared to a current price of kr1,039.91 — trading 91.3% below its estimated fair value. The current Revenue is kr16.07 Mil. Oncoinvent ASA's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Oncoinvent ASA (CHIX:ONCINO), the current Revenue is kr16.07 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of kr1,039.91 is trading 91.3% below its estimated GF Value™ of kr11,961.53.
Key valuation signals for CHIX:ONCINO:
Revenue: kr16.07 Mil
GF Value™: kr11,961.53 vs. price of kr1,039.91 (91.3% below fair value)
No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score
Get the complete analysis for CHIX:ONCINO
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ONCINO has been successfully added to your 
